NCT06604169Active, not recruiting
An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death
Source: ClinicalTrials.gov · Last updated 19 Sept 2024
Brief summary (registry, in English)
1. To observe the failure rate of S-ICD screening in HCM patients at high risk of SCD. 2. To observe the incidence of IAS in HCM patients with S-ICD implantation and explore the related factors of IAS.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 589 (estimated)
- First submitted
- 18 Sept 2024
- Start date
- 1 Aug 2024
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT06604169
What you commit to
- Study type: Observational
- Planned participants: 589
- From 1 Aug 2024 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Frequent monomorphic ventricular tachycardia require ATP therapy;
Other illness
- Combined with other diseases, life expectancy is less than 1 year.
Other
- Combined with bradycardia with pacing indications;
- With indications of CRT;
Who the study is looking for
- HCM patients assessed as meeting the ICD implantation indication
Age in the registry: 14 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fuwai Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.